Chronic kidney disease therapeutic - Eli Lilly
Latest Information Update: 06 Jun 2014
At a glance
- Originator Eli Lilly
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Kidney disorders
Most Recent Events
- 06 Jun 2014 No development reported - Phase-I for Kidney disorders in USA (Parenteral)
- 15 Jul 2012 Phase-I clinical trials in Kidney disorders in USA (Parenteral)